In vitro and in vivo activity of 1-O-hexadecylpropanediol -3-phospho-ganciclovir and 1-O-hexadecylpropanediol -3-phospho-penciclovir in cytomegalovirus and herpes simplex virus infections

Antiviral Chemistry and Chemotherapy

Volumn 12, Issue 1, 2001, Pages 61-70

  Hostetler, K Y ^a   Rybak, R J ^a   Beadle, J R ^a   Gardner, M F ^a   Aldern, K A ^a   Wright, K N ^a   Kern, E R ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Antivirals; Cytomegalovirus; Ganciclovir; Herpes simplex virus; Penciclovir; Prodrugs

Indexed keywords

1 O HEXADECYLPROPANEDIOL 3 PHOSPHOGANCICLOVIR; 1 O HEXADECYLPROPANEDIOL 3 PHOSPHOPENCICLOVIR; ANTIVIRUS AGENT; GANCICLOVIR; PENCICLOVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SYNTHESIS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; MORTALITY; PRIORITY JOURNAL;

EID: 0034973557     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020101200104     Document Type: Article

References (31)

1. Metabolic activation of the nucleoside analog 9[2-hydroxy-1-(hydroxymethyl)-ethoxy]methylguanine in human diploid fibroblasts infected with human cytomegalovirus
2. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment
3. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers
4. Foscarnet: A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with CMV retinkis
5. In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir
6. Cytomegalovirus infection in patients with AIDS
7. Ganciclovir: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections
8. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine: The Zidovudine Epidemology Group
9. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high risk kidney transplant patients
10. Synthesis and antiviral activity of 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]purines
11. Cidofovir, a new agent with potent antiherpesvirus activity
12. Antiviral activity of oral 1-O-hexadecylpropanediol-3-phospho-acyclovir and acyclovir in woodchucks with chronic woodchuck hepatitis virus infection
13. Enhanced oral absorption and antiviral activity of 1-O-octadecyl-sn-glycero-3-phospho-acyclovir in hepatitis B virus infection, in vitro
14. Lipid prodrugs of phosphono-acids: Greatly enhanced antiviral activity of 1-O-octadecyl-sn-glycero-3-phosphonoformate in HIV-1, HSV-1 and HCMV-infected cells, in vitro
15. Human pharmacokinetics and tolerance of oral ganciclovir
16. Foscarnet treatment of CMV retinitis in patients with AIDS
17. Serious cytomegalovirus disease in AIDS: Clinical findings, diagnosis and treatment
18. Herpesvirus hominis infection in newborn mice. I. An experimental model and therapy with iododeoxyuridine
19. Alkoxypropane prodrugs of foscarnet: Effect of alkoxy chain length on in vitro antiviral activity in cells infected with HIV-1, HSV-1 and HCMV
20. Synthesis and antiviral activity of 1-O-octadecyl-2-O-alkyl-sn-glycero-3-foscarnet conjugates in human cytomegalovirus-infected cells
21. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial
22. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral analogue ganciclovir
23. Antiviral activity and mechanism of action of ganciclovir
24. Absorption and metabolism of lecithin and lysolecithin by intestinal slices
25. (Z)- and (E)-2-(hydroxymethyl)cyclopropylidene)-methyladenine and -guanine. New nucleoside analogues with a broad-spectrum antiviral activity
26. Incorporation of dietary lecithin and lysolecithin into lymph chylomicrons in the rat
27. Activity of GCV in the treatment of CVM pneumonia
28. Pharmacokinetic, safety and antiviral profiles of oral ganviclovir in persons infected with HIV: A Phase I/II study
29. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: A randomized clinical trial
30. A randomized, controlled study of intravenous GCV therapy for CMV peripheral retinitis in patients with AIDS
31. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells